Abstract:Background: Available evidence shows that the incidence of toxicities associated with cancer immunotherapy, such as programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1)-related toxicities, is estimated to be between 0.3 and 1.3%. Objective: This systematic review aimed to investigate cancer patients' susceptibility to toxicities associated with PD-1/PD-L1 inhibitors and establish a clinically relevant landscape of side effects of PD-1/PD-L1 inhibitors. Data sources: Relevant publications from PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure (CNKI) between 2014 and 2019. Study eligibility criteria, participants, and interventions: We searched randomized controlled trials (RCTs) reporting treatment-related toxicities associated with PD-1 and PD-L1 inhibitors in the treatment of cancers. The primary endpoint was to assess the difference in the incidences of toxicities between cancer patients who did and did not receive PD-1/PD-L1 inhibitors. A total of 29 RCTs, incorporating 8576 patients, met the eligibility criteria. Study appraisal and synthesis methods: We calculated the pooled relative risks and corresponding 95% CIs using a random-effects model and assessed the heterogeneity between different groups. The subgroup analyses were conducted based on cancer type, toxicity grade (severity), system and organ, treatment regimens in the intervention arm and the control arm, PD-1/PD-L1 inhibitor drug type, and cancer type. Results: A total of 11 categories (e.g. endocrine toxicity), and 39 toxicity types (e.g. hyperthyroidism) were identified. For toxicities at any grade, those treated with PD-1/PD-L1 inhibitors were at lower risks for gastrointestinal toxicity, hematologic toxicity, and treatment event leading to discontinuation; and were at higher risks for respiratory toxicity (all P <0.05). Those treated with PD-1/PD-L1 inhibitors were at lower risks for fatigue, asthenia, and peripheral edema and were at higher risks for pyrexia, cough, dyspnea, pneumonitis, and pruritus. Limitations: The present research is a meta-analysis at the study level rather than at the patient level; insights on risk factors associated with the development of toxicities cannot be found in our study. There was a possible overlap in Common Terminology Criteria for Adverse Events (CTCAE) definitions which prevents understanding the true rates of specific toxicities. Conclusions and implications of key findings: For most toxicity types based on system and organ, the incidence proportions for patients in the intervention arm were lower than those in the control arm, which suggested the general safety of PD-1/PD-L1 inhibitors against conventional chemotherapy and cytotoxic t-lymphocyte-associated protein 4 (CTLA-4) inhibitors. Future research should focus on taking effective targeted measures to decrease the risks of different toxicities for different patient populations. Systematic review registration number: We registered the research protocol with PROSPERO (registration number CRD42019135113).

The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer

Current Status of PD-(L)1 Inhibitor Usage in Advanced or Metastatic Non-Small Cell Lung Cancer: A National Survey of Oncologists in China.

Pd-1 Inhibitors Increase the Incidence and Risk of Pneumonitis in Cancer Patients in A Doseindependent Manner: A Metaanalysis

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer

OA21.01 Pooled Analysis of the Incidence and Risk of Treatment-Related Pneumonitis with Anti-PD-1/PD-L1 Therapies in Cancer Patients

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis

Safety and Tolerability of PD-1/PD-L1 Inhibitors in the Treatment of Non-Small Cell Lung Cancer: a Meta-Analysis of Randomized Controlled Trials

Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials

Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.

Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions

Safety and Efficacy of Anti-Pd-1 Inhibitors in Chinese Patients with Advanced Lung Cancer and Hepatitis B Virus Infection: a Retrospective Single-Center Study

P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer

Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis.

Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

The Safety and Efficacy of Immunotherapy with Anti-Programmed Cell Death 1 Monoclonal Antibody for Lung Cancer Complicated with Mycobacterium Tuberculosis Infection

Toxicities associated with immune checkpoint inhibitors: a systematic study

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study

Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors Versus Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer: a Meta Analysis of Randomized Controlled Trials.

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.